Dillard R D, Bach N J, Draheim S E, Berry D R, Carlson D G, Chirgadze N Y, Clawson D K, Hartley L W, Johnson L M, Jones N D, McKinney E R, Mihelich E D, Olkowski J L, Schevitz R W, Smith A C, Snyder D W, Sommers C D, Wery J P
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA.
J Med Chem. 1996 Dec 20;39(26):5119-36. doi: 10.1021/jm960485v.
Phospholipases (PLAs) produce rate-limiting precursors in the biosynthesis of various types of biologically active lipids involved in inflammatory processes. Increased levels of human nonpancreatic secretory phospholipase A2 (hnps-PLA2) have been detected in several pathological conditions. An inhibitor of this enzyme could have therapeutic utility. A broad screening program was carried out to identify chemical structures which could inhibit hnps-PLA2. One of the lead compounds generated by the screening program was 5-methoxy-2-methyl-1-(phenylmethyl)-1H-indole-3-acetic acid (13a). We describe the syntheses, structure--activity relationships, and pharmacological activities of a series of indole-3-acetamides and related compounds derived from this lead. This SAR was undertaken with the aid of X-ray crystal structures of complexes between the inhibitors and hnps-PLA2 which were of great value in directing the SAR.
磷脂酶(PLAs)在参与炎症过程的各类生物活性脂质的生物合成中产生限速前体。在多种病理状况下已检测到人类非胰腺分泌型磷脂酶A2(hnps-PLA2)水平升高。该酶的抑制剂可能具有治疗作用。开展了一项广泛的筛选计划以鉴定能够抑制hnps-PLA2的化学结构。筛选计划产生的先导化合物之一是5-甲氧基-2-甲基-1-(苯甲基)-1H-吲哚-3-乙酸(13a)。我们描述了一系列源自该先导化合物的吲哚-3-乙酰胺及相关化合物的合成、构效关系和药理活性。这种构效关系是借助抑制剂与hnps-PLA2之间复合物的X射线晶体结构进行的,这些结构在指导构效关系方面具有重要价值。